Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung

Abstract

Our data suggest that mucinous adenocarcinoma is typified by (1) frequent KRAS mutations and a growing list of gene fusions, but rare TP53 mutations, (2) a low mutation burden overall, and (3) a recurrence-free survival similar to stage-matched nonmucinous tumors, with recurrences limited to the lungs.

Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB

“…A small cohort study (Bueno et al 2015;Coutinho et al 2016) found no clear benefit for the NCCN's highrisk patients for OS and DFS. A recent meta-analysis (Shim et al 2015) included 16 randomized trials indicated that adjuvant chemotherapy was beneficial for OS and DFS in patients with stage IB NSCLC, but the conclusion was not definitive when considering the overall heterogeneity of OS and DFS. In our study, we found that ACT has positive effect on reduce recurrence, with a 8.4 % improvement of 5-year disease-free survival, but there was no advantage in prolonging overall survival.…”

Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma

“…Many previous cohort studies (Cai et al 2014;Shim et al 2015) included all stage of IMA patients, which patients in stage I account for the majority, reported that there was no distinct prognostic difference between invasive mucinous and nonmucinous adenocarcinoma. Those results were consistent with our study.…”

“…(IMA), formerly diagnosed as mucinous bronchioloalveolar (BCA), is recognized as a variant adenocarcinoma subtype with a rare incidence, account for approximately 5 % of all lung adenocarcinomas (Shim et al 2015;Travis et al 2011). Invasive mucinous adenocarcinoma is distinguished for nonmucinous adenocarcinoma for its differences in morphological, genetic and clinical characteristics.…”

Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma

“…In addition, based on the results of Cancer Genome Atlas exome data analysis, there is a concerning link between P53 status and mutation burden in tumors (21). In other words, the evaluation of P53 status could be used as a surrogate biomarker for mutation burden (9,21). At the same time, other research has suggested that higher non-synonymous mutation burdens could improve clinical benefits and PFS after antitumor therapy (22).…”

“…To our knowledge, this is the first report concerning the prognostic significance of P53 expression in LELC of the lung. In addition, based on the results of Cancer Genome Atlas exome data analysis, there is a concerning link between P53 status and mutation burden in tumors (21). In other words, the evaluation of P53 status could be used as a surrogate biomarker for mutation burden (9,21).…”